Federal Circuit’s Holding on Patent Eligibility for Engineered Host Cells Dovetails With PERA

Why It Matters

The ruling could broaden protection for engineered biological tools, influencing R&D investment and shaping the legislative push behind PERA. It also signals how courts may interpret patent eligibility for recombinant DNA constructs moving forward.

Key Takeaways

• Federal Circuit deems engineered host cells patent‑eligible under §101.
• Decision aligns with PERA’s goal to reduce eligibility uncertainty.
• Sarepta seeks en banc rehearing, arguing natural DNA sequences.
• Potential precedent for broader biotech patent protection on recombinant constructs.

Pulse Analysis

The Federal Circuit’s latest opinion arrives at a pivotal moment for biotechnology patent law, a field still wrestling with the Supreme Court’s landmark decisions in Mayo, Myriad and Alice. Those cases introduced a stringent two‑step test that often left courts uncertain about where to draw the line between natural phenomena and human‑made inventions. By revisiting the Chakrabarty doctrine—where a genetically modified bacterium was deemed patent‑eligible—the court reasserts that a substantive transformation, not merely a combination of natural elements, can satisfy §101 requirements. This nuanced approach helps clarify the legal landscape that has been fragmented for years.

In REGENXBIO v. Sarepta, the panel focused on a host cell that harbors a recombinant nucleic‑acid molecule encoding an adeno‑associated virus capsid protein alongside a heterologous sequence. The court emphasized that the engineered construct could not arise in nature without deliberate human manipulation, thereby meeting the “material change” threshold. Moreover, the opinion introduced a utility‑centric lens, asking whether the claimed composition possesses significant, even implicit, utility—a factor that dovetails with the objectives of the Patent Eligibility Restoration Act of 2025. PERA aims to replace vague judicial exceptions with explicit statutory exclusions, and the decision illustrates how legislation and case law can converge to reduce uncertainty for innovators.

For biotech firms, the ruling signals a more favorable environment for securing patents on complex recombinant tools, potentially unlocking new revenue streams and encouraging investment in gene‑therapy platforms. However, the ongoing en banc petition by Sarepta highlights that litigation risk remains, especially as opponents argue that such patents could monopolize fundamental research tools. Stakeholders should monitor congressional action on PERA, as its passage could cement the court’s reasoning into statutory law, providing a more predictable framework for future biotech patent strategies.